GC Corp

10% Owner GC Corp buys 1,432,291 shares ($16.5M) at $11.52 amid 47.6% decline from 52-week high

GC Corp, a 10% owner at Artiva Biotherapeutics, executed 2 separate purchases totaling 1,432,291 shares (1.43M shares) for $16,499,992.32 ($16.5M) at a blended average price of $11.52, expanding holdings from 175,443 to 1,607,734 shares (+816.4%). The transaction occurs as the stock trades at $7.61, representing a -47.6% decline from the 52-week high of $14.53 and a -16.1% drop over the prior 30 days. The company's fundamentals are strained: latest-quarter revenue totaled $251,000.00 ($251.0K), annual revenue contracted by -100.0%, and net income was negative $-23,516,000.00 ($-23.5M) over the most recent full fiscal year. GC Corp's prior buy activity at this same ticker (2 prior trades on 2024-07-22) both exhibited +1.4% 90-day returns, suggesting a pattern of well-timed entry points at this specific security, though the current substantially lower price level and accelerated cash burn relative to declining revenue represent material context shifts that warrant investor attention.

10% owner GC Corp. buys 2,083,332 shares in ARTV for $24,999,984.00 in 2 transactions; cluster buy pattern with 4 other insiders in 14 days

GC Corp., a 10% owner of Artiva Biotherapeutics, executed 2 separate purchases totaling 2,083,332 shares for $24,999,984.00 on 2024-07-22 at $12.00 per share. The transaction occurred within days of the company's recent listing (2 trading days old). This filing reflects a conversion of derivative securities rather than a simple equity purchase, meaning the insider's true position includes both Table I shares (1,260,512 post-transaction) and unconverted derivative holdings not yet visible in this database. Notably, 4 other insiders also purchased shares within the past 14 days, establishing a cluster buy pattern that suggests coordinated confidence in the near-post-IPO window. The scale of this single transaction—nearly $25M at a 10% ownership stake—alongside the broader insider activity warrants attention to how the market prices the business relative to insider acquisition timing.